Crispr Therapeutics (CRSP) Shares Down 7%

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) dropped 7% on Monday . The stock traded as low as $37.12 and last traded at $37.75. Approximately 584,627 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 729,837 shares. The stock had previously closed at $40.59.

A number of research firms recently weighed in on CRSP. Citigroup cut shares of Crispr Therapeutics from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $28.00 to $21.00 in a research report on Tuesday, January 22nd. Goldman Sachs Group cut shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $78.00 to $40.00 in a research report on Monday, January 28th. BTIG Research began coverage on shares of Crispr Therapeutics in a research report on Thursday, February 7th. They set a “buy” rating and a $43.00 price objective for the company. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. Finally, William Blair began coverage on shares of Crispr Therapeutics in a research report on Wednesday, March 13th. They set a “market perform” rating for the company. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $47.64.

The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -10.97 and a beta of 3.11. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08.



Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.03). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. Crispr Therapeutics’s quarterly revenue was down 78.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.62) earnings per share. As a group, analysts predict that Crispr Therapeutics AG will post -3.82 earnings per share for the current year.

In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $42.03, for a total transaction of $840,600.00. Following the sale, the chief executive officer now directly owns 186,542 shares in the company, valued at approximately $7,840,360.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, President Rodger Novak sold 85,220 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.40, for a total transaction of $3,442,888.00. Following the sale, the president now owns 1,024,534 shares in the company, valued at $41,391,173.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 128,693 shares of company stock worth $5,222,495. 37.70% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Versant Venture Management LLC lifted its holdings in Crispr Therapeutics by 17.7% during the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock worth $151,770,000 after buying an additional 640,014 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Crispr Therapeutics by 52.7% in the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock valued at $72,262,000 after purchasing an additional 697,907 shares in the last quarter. Federated Investors Inc. PA raised its holdings in shares of Crispr Therapeutics by 21.0% in the 3rd quarter. Federated Investors Inc. PA now owns 764,263 shares of the company’s stock valued at $33,895,000 after purchasing an additional 132,863 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Crispr Therapeutics by 19.6% in the 3rd quarter. BlackRock Inc. now owns 709,643 shares of the company’s stock valued at $31,471,000 after purchasing an additional 116,116 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in shares of Crispr Therapeutics in the 4th quarter valued at $16,598,000. Institutional investors own 43.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Crispr Therapeutics (CRSP) Shares Down 7%” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://dakotafinancialnews.com/2019/05/14/crispr-therapeutics-crsp-shares-down-7.html.

About Crispr Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Different Types of Derivatives

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.